402 related articles for article (PubMed ID: 26371289)
21. Irinotecan and its metabolite SN38 inhibits procollagen I production of dermal fibroblasts from Systemic Sclerosis patients.
Lapoirie J; Tran L; Piazza L; Contin-Bordes C; Truchetet ME; Bonnet F
Sci Rep; 2021 Sep; 11(1):18011. PubMed ID: 34504265
[TBL] [Abstract][Full Text] [Related]
22. Histone modifications underlie monocyte dysregulation in patients with systemic sclerosis, underlining the treatment potential of epigenetic targeting.
van der Kroef M; Castellucci M; Mokry M; Cossu M; Garonzi M; Bossini-Castillo LM; Chouri E; Wichers CGK; Beretta L; Trombetta E; Silva-Cardoso S; Vazirpanah N; Carvalheiro T; Angiolilli C; Bekker CPJ; Affandi AJ; Reedquist KA; Bonte-Mineur F; Zirkzee EJM; Bazzoni F; Radstake TRDJ; Rossato M
Ann Rheum Dis; 2019 Apr; 78(4):529-538. PubMed ID: 30793699
[TBL] [Abstract][Full Text] [Related]
23. Downregulated IRF8 in Monocytes and Macrophages of Patients with Systemic Sclerosis May Aggravate the Fibrotic Phenotype.
Ototake Y; Yamaguchi Y; Asami M; Komitsu N; Akita A; Watanabe T; Kanaoka M; Kurotaki D; Tamura T; Aihara M
J Invest Dermatol; 2021 Aug; 141(8):1954-1963. PubMed ID: 33705797
[TBL] [Abstract][Full Text] [Related]
24. Serum concentration of procollagen type I carboxyterminal propeptide in systemic sclerosis.
Kikuchi K; Ihn H; Sato S; Igarashi A; Soma Y; Ishibashi Y; Takehara K
Arch Dermatol Res; 1994; 286(2):77-80. PubMed ID: 8154928
[TBL] [Abstract][Full Text] [Related]
25. Correlation of interferon-inducible chemokine plasma levels with disease severity in systemic sclerosis.
Liu X; Mayes MD; Tan FK; Wu M; Reveille JD; Harper BE; Draeger HT; Gonzalez EB; Assassi S
Arthritis Rheum; 2013 Jan; 65(1):226-35. PubMed ID: 23055137
[TBL] [Abstract][Full Text] [Related]
26. Circulating collagen metabolites in systemic sclerosis. Differences between limited and diffuse form and relationship with pulmonary involvement.
Scheja A; Wildt M; Wollheim FA; Akesson A; Saxne T
Rheumatology (Oxford); 2000 Oct; 39(10):1110-3. PubMed ID: 11035131
[TBL] [Abstract][Full Text] [Related]
27. A novel multi-network approach reveals tissue-specific cellular modulators of fibrosis in systemic sclerosis.
Taroni JN; Greene CS; Martyanov V; Wood TA; Christmann RB; Farber HW; Lafyatis RA; Denton CP; Hinchcliff ME; Pioli PA; Mahoney JM; Whitfield ML
Genome Med; 2017 Mar; 9(1):27. PubMed ID: 28330499
[TBL] [Abstract][Full Text] [Related]
28. Circulating γ/δ T cells in systemic sclerosis exhibit activated phenotype and enhance gene expression of proalpha2(I) collagen of fibroblasts.
Ueda-Hayakawa I; Hasegawa M; Hamaguchi Y; Takehara K; Fujimoto M
J Dermatol Sci; 2013 Jan; 69(1):54-60. PubMed ID: 23159281
[TBL] [Abstract][Full Text] [Related]
29. MiR-30a-3p negatively regulates BAFF synthesis in systemic sclerosis and rheumatoid arthritis fibroblasts.
Alsaleh G; François A; Philippe L; Gong YZ; Bahram S; Cetin S; Pfeffer S; Gottenberg JE; Wachsmann D; Georgel P; Sibilia J
PLoS One; 2014; 9(10):e111266. PubMed ID: 25360821
[TBL] [Abstract][Full Text] [Related]
30. Possible association of elevated serum collagen type IV level with skin sclerosis in systemic sclerosis.
Motegi SI; Sekiguchi A; Fujiwara C; Toki S; Ishikawa O
J Dermatol; 2017 Feb; 44(2):167-172. PubMed ID: 27568491
[TBL] [Abstract][Full Text] [Related]
31. Angiopoietin-2 Promotes Inflammatory Activation in Monocytes of Systemic Sclerosis Patients.
Carvalheiro T; Lopes AP; van der Kroef M; Malvar-Fernandez B; Rafael-Vidal C; Hinrichs AC; Servaas NH; Bonte-Mineur F; Kok MR; Beretta L; Zimmermann M; Marut W; Pego-Reigosa JM; Radstake TRDJ; Garcia S
Int J Mol Sci; 2020 Dec; 21(24):. PubMed ID: 33333969
[TBL] [Abstract][Full Text] [Related]
32. Serum aminoterminal propeptide of type III procollagen in systemic sclerosis. A follow-up--investigations in subclasses and during therapy.
Heickendorff L; Parvez A; Bjerring P; Halkier-Sørensen L; Zachariae H
Acta Derm Venereol; 1991; 71(3):185-8. PubMed ID: 1678217
[TBL] [Abstract][Full Text] [Related]
33. Low RUNX3 expression alters dendritic cell function in patients with systemic sclerosis and contributes to enhanced fibrosis.
Affandi AJ; Carvalheiro T; Ottria A; Broen JC; Bossini-Castillo L; Tieland RG; Bon LV; Chouri E; Rossato M; Mertens JS; Garcia S; Pandit A; de Kroon LM; Christmann RB; Martin J; van Roon JA; Radstake TR; Marut W
Ann Rheum Dis; 2019 Sep; 78(9):1249-1259. PubMed ID: 31126957
[TBL] [Abstract][Full Text] [Related]
34. Carboxyterminal type I procollagen peptide concentrations in systemic sclerosis: higher levels in early diffuse disease.
Scheja A; Hellmer G; Wollheim FA; Akesson A
Br J Rheumatol; 1993 Jan; 32(1):59-62. PubMed ID: 8422562
[TBL] [Abstract][Full Text] [Related]
35. Identification of NF-κB and PLCL2 as new susceptibility genes and highlights on a potential role of IRF8 through interferon signature modulation in systemic sclerosis.
Arismendi M; Giraud M; Ruzehaji N; Dieudé P; Koumakis E; Ruiz B; Airo P; Cusi D; Matucci-Cerinic M; Salvi E; Cuomo G; Hachulla E; Diot E; Caramaschi P; Riccieri V; Avouac J; Kayser C; Allanore Y
Arthritis Res Ther; 2015 Mar; 17(1):71. PubMed ID: 25880423
[TBL] [Abstract][Full Text] [Related]
36. The magnitude of cytokine production by stimulated CD56
Cossu M; van Bon L; Nierkens S; Bellocchi C; Santaniello A; Dolstra H; Beretta L; Radstake TR
Clin Immunol; 2016 Dec; 173():76-80. PubMed ID: 27616458
[TBL] [Abstract][Full Text] [Related]
37. Anti-CXCL4 Antibody Reactivity Is Present in Systemic Sclerosis (SSc) and Correlates with the SSc Type I Interferon Signature.
Lande R; Mennella A; Palazzo R; Pietraforte I; Stefanantoni K; Iannace N; Butera A; Boirivant M; Pica R; Conrad C; Chizzolini C; Riccieri V; Frasca L
Int J Mol Sci; 2020 Jul; 21(14):. PubMed ID: 32707718
[TBL] [Abstract][Full Text] [Related]
38. Monocyte chemoattractant protein 3 as a mediator of fibrosis: Overexpression in systemic sclerosis and the type 1 tight-skin mouse.
Ong VH; Evans LA; Shiwen X; Fisher IB; Rajkumar V; Abraham DJ; Black CM; Denton CP
Arthritis Rheum; 2003 Jul; 48(7):1979-91. PubMed ID: 12847692
[TBL] [Abstract][Full Text] [Related]
39. Increased levels of amino terminal propeptide of type III procollagen are an unfavourable predictor of survival in systemic sclerosis.
Nagy Z; Czirják L
Clin Exp Rheumatol; 2005; 23(2):165-72. PubMed ID: 15895885
[TBL] [Abstract][Full Text] [Related]
40. Increased expression of 2'5'oligoadenylate synthetase and double-stranded RNA dependent protein kinase messenger RNAs on affected skin of systemic sclerosis patients.
Coelho LF; de Oliveira JG; de Oliveira DB; Guedes AC; Lanna CC; Prados RZ; Ferreira PC; Bonjardim CA; Kroon EG
Arch Dermatol Res; 2007 Aug; 299(5-6):259-62. PubMed ID: 17541615
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
